ATAI News and Press, ATAI Life Sciences N.V. From 01/10/22

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: ...

At the start of last year, only a few psychedelic companies were trading on the exchange markets , with Compass Pathways (NASDAQ: CMPS) and Mind Medicine (NASDAQ: MNMD) (NEO: MMED)  (“MindMed”) among them. However, this year saw a number of IPOs, which increased the to...

Rezolve has entered into a definitive business combination agreement with Cohen & Company backed Armada Acquisition Corp. I (NASDAQ: AACI) Deal positions Rezolve as a leader of Mobile Commerce transformation globally Powerful partner driven business model positions...

atai Impact, the recently established philanthropic program of German pharma company, atai Life Sciences (NASDAQ:ATAI), announced a collaboration with Massachusetts General Hospital (MGH). In partnership with the Center for the Neuroscience of Psychedelics of MGH, atai Impact has launched its...

Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...

“Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly.” That’s what Harvard researchers stated in Why Innovation in Health Care Is So Hard ...

atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help unlock the mysteries of the brain, improve the treatment of mental health ...

atai Life Sciences (ATAI -23.4%) discloses that a group of largest pre-IPO investors representing over 30% of the company’s common stock have voluntarily agreed for renewed lock-up agreements extending the trading restrictions of pre-IPO shares for up to 24 months. Among them is Apeiro...

Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...

• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • Demonstrates strong ongoing confidence in atai’...